Inhibitory action of pristimerin on hypoxia-mediated metastasis involves stem cell characteristics and EMT in PC-3 prostate cancer cells

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1388-1394

  Zuo, Jianwei ^a   Guo, Yuanqing ^a   Peng, Xinsheng ^a   Tang, Yubo ^a   Zhang, Xintao ^b   He, Peiheng ^a   Li, Shuaihua ^a   Wa, Qingde ^a   Li, Jinglei ^c   Huang, Shuai ^a   Xu, Dongliang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Bone metastasis; Cancer stem cells; EMT; Hypoxia; Prostate cancer

Indexed keywords

ARGONAUTE 2 PROTEIN; CHOLECYSTOKININ OCTAPEPTIDE; FIBRONECTIN; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KRUPPEL LIKE FACTOR 4; NERVE CELL ADHESION MOLECULE; OCTAMER TRANSCRIPTION FACTOR 4; PRISTIMERIN; TRANSCRIPTION FACTOR ZEB1; VIMENTIN; ANTINEOPLASTIC AGENT; ARGONAUTE PROTEIN; CADHERIN; CD44 PROTEIN, HUMAN; EIF2C2 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; KRUPPEL LIKE FACTOR; POU5F1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRITERPENE; ZEB1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER STEM CELL; CELL ASSAY; CELL INVASION ASSAY; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL STRUCTURE; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS INHIBITION; PC 3 CELL LINE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SPHEROID FORMATION ASSAY; WESTERN BLOTTING; BIOSYNTHESIS; BONE NEOPLASMS; CELL HYPOXIA; CELL TRANSFORMATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; MALE; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; TUMOR CELL CULTURE; TUMOR INVASION;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; ARGONAUTE PROTEINS; BONE NEOPLASMS; CADHERINS; CELL HYPOXIA; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PROSTATIC NEOPLASMS; SPHEROIDS, CELLULAR; TRANSCRIPTION FACTORS; TRITERPENES; TUMOR CELLS, CULTURED; VIMENTIN;

EID: 84921677183     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3708     Document Type: Article

References (35)

1. Duffy MJ, McGowan PM and Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol 214:283-293, 2008.
2. Carlin BI and Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88(Suppl 12):S2989-S2994, 2000.
3. Papachristou DJ, Basdra EK and Papavassiliou AG: Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev 32:611-636, 2012.
4. Höckel M and Vaupel P: Biological consequences of tumor hypoxia. Semin Oncol 28(Suppl 8):S36-S41, 2001.
5. Greco O, Marples B, Joiner MC and Scott SD: How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 197:312-325, 2003.
6. Brizel DM, Scully SP, Harrelson JM, et al: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56:941-943, 1996.
7. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732, 2003.
8. Wang GL and Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230-1237, 1995.
9. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59:5830-5835, 1999.
10. Blagosklonny MV: Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (Review). Int J Oncol 19:257-262, 2001.
11. Maxwell PH, Dachs GU, Gleadle JM, et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104-8109, 1997.
12. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331:1559-1564, 2011.
13. Monteiro J and Fodde R: Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 46:1198-1203, 2010.
14. Marignol L, Coffey M, Lawler M and Hollywood D: Hypoxia in prostate cancer: a powerful shield against tumour destruction. Cancer Treat Rev 34:313-327, 2008.
15. Sharifi N, Kawasaki BT, Hurt EM and Farrar WL: Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 5:901-906, 2006.
16. Pfeiffer MJ and Schalken JA: Stem cell characteristics in prostate cancer cell lines. Eur Urol 57:246-254, 2010.
17. Ma Y, Liang D, Liu J, et al: Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 6:e29170, 2011.
18. Marie-Egyptienne DT, Lohse I and Hill RP: Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett 341:63-72, 2013.
19. Higgins DF, Kimura K, Bernhardt WM, et al: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117:3810-3820, 2007.
20. Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740-746, 2003.
21. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646-674, 2011.
22. Nauseef JT and Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 8:428-439, 2011.
23. Sethi S, Macoska J, Chen W and Sarkar FH: Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3:90-99, 2010.
24. Liu YB, Gao X, Deeb D, Arbab AS and Gautam SC: Pristimerin induces apoptosis in prostate cancer cells by down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal degradation pathway. J Carcinog Mutagen (Suppl 6):005, 2013.
25. Peng X, Guo W, Liu T, et al: Identification of miRs-143 and-145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6:e20341, 2011.
26. Huang S, Guo W, Tang Y, Ren D, Zou X and Peng X: miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep 28:1831-1837, 2012.
27. Liao D, Corle C, Seagroves TN and Johnson RS: Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67:563-572, 2007.
28. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768, 2008.
29. Bisson I and Prowse DM: WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 19:683-697, 2009.
30. Warfel NA and El-Deiry WS: HIF-1 HIF-1 signaling in drug resistance to chemotherapy. Curr Med Chem 21:3021-3028, 2014.
31. Hayashida T, Jinno H, Kitagawa Y and Kitajima M: Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol 2011:591427, 2011.
32. Duggal R, Minev B, Geissinger U, et al: Biotherapeutic approaches to target cancer stem cells. J Stem Cells 8:135-149, 2013.
33. Xu J, Wang R, Xie ZH, et al: Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66:1664-1673, 2006.
34. Whitbread AK, Veveris-Lowe TL, Lawrence MG, Nicol DL and Clements JA: The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition. Biol Chem 387:707-714, 2006.
35. Kasper S and Cookson MS: Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33:201-210, vii, 2006.